Cipla Limited (CIPLA) Share Price

NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE059A01026

₹1,397.70+3.00 (+0.22%)

Key metrics

Market Cap
₹1.12 L Cr
P/E Ratio
33.21
EPS
41.7
Book Value
427.35
P/B Ratio
3.27
ROE
11.24%
ROCE
13.79%
Debt / Equity
0.02
Net Margin
14%
Revenue Growth
2.09%
Profit Growth
-26.43%
Dividend Yield
0.93%
52W High
₹1,673.00
52W Low
₹1,165.70
Market Cap Band
large cap
Face Value
2

Ratios computed from the annual results period ending 2026-03-31.

About Cipla Limited

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Headquarters
Mumbai, India
Employees
31,369
Promoter Holding
31.13%

The full Cipla Limited analysis

Create a free account to open the complete CIPLA deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.

  • 10-year financialsIncome statement, balance sheet and cash flow, year by year.
  • Valuation & fair valueFair-value estimates, quality scores and a value grade.
  • Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
  • Shareholding historyPromoter, FII, DII and public holdings across every quarter.
  • Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
  • Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.